Intended Audience
This continuing education program was designed specifically for pharmacists and pharmacy technicians.
Pharmacist Learning Objectives:
At the completion of this activity, pharmacists will be able to:
1. Describe the mechanism of action and toxicities of lurbinectedin.
2. Evaluate the evidence supporting pembrolizumab for treatment of MSI-H colorectal cancer.
3. Discuss the strengths and limitations of oral azacitidine for maintenance AML treatment.
4. Design a monitoring and management plan for belantamab-induced ocular toxicities.
To view the full agenda, click here.
Continuing Education Credits:
1.0 contact hour; Knowledge-based; Release Date: 05/18/21; Expiration Date: 05/15/22
Michigan Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.